Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kangtai hepatitis B vaccine
- Development stage
- Unknown
- Lead developer
- Shenzhen Kangtai Biological Products
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Kangtai hepatitis B vaccine is a recombinant protein subunit vaccine produced in yeast (Saccharomyces cerevisiae) expressing the hepatitis B surface antigen (HBsAg). Developed by Shenzhen Kangtai Biological Products (Bio-Kangtai), it is designed for active immunization against hepatitis B virus (HBV) infection. The vaccine is available in various strengths, including a high-dose 60 μg formulation specifically intended for adults who are non-responders or low-responders to conventional 20 μg doses. It has been evaluated in clinical trials for both standard (0, 1, 6 months) and rapid (0, 2 months) immunization schedules to provide flexible and effective protection against HBV. The vaccine works by inducing the production of specific antibodies (anti-HBs) that neutralize the hepatitis B virus.
- Brand names
- Kangtai hepatitis B vaccine
- Other names
- Bio-Kangtai hepatitis B vaccine60 μg recombinant hepatitis B vaccine (Saccharomyces cerevisiae)Shenzhen Kangtai hepatitis B vaccine
02
Targets
HBV (Hepatitis B virus)
Beyond the preview
Go deeper on Kangtai hepatitis B vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kangtai hepatitis B vaccine.